BMRNBioMarin Pharmaceutical Inc.

BMRN Stock Price, Valuation & Chart | BioMarin Pharmaceutical Inc.

Compare

$64.840-0.39 (-0.60%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology BMRN intrinsic value BMRN calculated fair value vs price

Overview Financials Dividends Ratios

BMRN Historical price chart

BMRN Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization12.53B

PE Ratio31.17

EPS2.08

Trading Volume1.78M

Today's High/Low66.02/64.49

Dividend Yield0.00

52 Week High/Low70.98/49.26

Shares Outstanding193.28M

BMRN Financial Statement

BMRN Analyst ratings

BMRN Analysis & performance metrics

BMRN Company profile

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products…

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for…

BMRN Management team

Name

Position

Ganesh Vedantham Ph.D.

Senior Vice President of Technical Development

George Eric Davis J.D.

Executive Vice President, Chief Legal Officer, General Counsel & Secretary

Gregory Friberg M.D.

Executive Vice President and Chief Research & Development Officer

Brian R. Mueller CPACFO

Executive Vice President of Finance & Chief Financial Officer

Cristin Hubbard

Executive Vice President & Chief Commercial Officer

Amy Wireman

Executive Vice President & Chief People Officer

Alexander HardyCEO

President, Chief Executive Officer & Director

Erin Burkhart

Group Vice President & Chief Accounting Officer

Name

Position

Ganesh Vedantham Ph.D.

Senior Vice President of Technical Development

George Eric Davis J.D.

Executive Vice President, Chief Legal Officer, General Counsel & Secretary

Gregory Friberg M.D.

Executive Vice President and Chief Research & Development Officer

Brian R. Mueller CPACFO

Executive Vice President of Finance & Chief Financial Officer

Cristin Hubbard

Executive Vice President & Chief Commercial Officer

Amy Wireman

Executive Vice President & Chief People Officer

Alexander HardyCEO

President, Chief Executive Officer & Director

Erin Burkhart

Group Vice President & Chief Accounting Officer

Management Team

Ganesh Vedantham Ph.D.

Senior Vice President of Technical Development

George Eric Davis J.D.

Executive Vice President, Chief Legal Officer, General Counsel & Secretary

Gregory Friberg M.D.

Executive Vice President and Chief Research & Development Officer

Brian R. Mueller CPACFO

Executive Vice President of Finance & Chief Financial Officer

Cristin Hubbard

Executive Vice President & Chief Commercial Officer

Amy Wireman

Executive Vice President & Chief People Officer

Alexander HardyCEO

President, Chief Executive Officer & Director

Erin Burkhart

Group Vice President & Chief Accounting Officer

Management

Ganesh Vedantham Ph.D.

Senior Vice President of Technical Development

George Eric Davis J.D.

Executive Vice President, Chief Legal Officer, General Counsel & Secretary

Gregory Friberg M.D.

Executive Vice President and Chief Research & Development Officer

Brian R. Mueller CPACFO

Executive Vice President of Finance & Chief Financial Officer

Cristin Hubbard

Executive Vice President & Chief Commercial Officer

Amy Wireman

Executive Vice President & Chief People Officer

Alexander HardyCEO

President, Chief Executive Officer & Director

Erin Burkhart

Group Vice President & Chief Accounting Officer

Total 8 executives

BMRN Frequently asked questions

What is BioMarin Pharmaceutical Inc. (BMRN) Stock Price?

Current stock price of BioMarin Pharmaceutical Inc. (BMRN) stock is $64.840. The stock price is -0.60% lower in the session. The intraday range can be seen from this page. Volume of BioMarin Pharmaceutical Inc. (BMRN) stock is 1.78M.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the BioMarin Pharmaceutical Inc. (BMRN) stock price going up or down today?

The stock price of BioMarin Pharmaceutical Inc. (BMRN) can change with earnings, company news, and overall market sentiment. BioMarin Pharmaceutical Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the BioMarin Pharmaceutical Inc. stock expensive at its current price?

Whether BioMarin Pharmaceutical Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for BMRN on this page is 31.17. EPS on this page is 2.08. Compare those figures with peers and growth expectations before deciding if the current BioMarin Pharmaceutical Inc. price is justified.

How has the stock price of BioMarin Pharmaceutical Inc. (BMRN) performed historically?

Historical performance for BioMarin Pharmaceutical Inc. (BMRN) is shown on the price chart on this page. Review multi-period moves alongside volume to see how BMRN reacted to past earnings and market events.

Should I buy BioMarin Pharmaceutical Inc. (BMRN) stock, at this price?

Buying BioMarin Pharmaceutical Inc. (BMRN) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.